Ser341
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser341  -  MDM4 (mouse)

Site Information
SKLTHsLstsNITAI   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 470031

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 5 ) , mass spectrometry ( 2 , 4 , 6 ) , mutation of modification site ( 1 , 3 , 5 ) , phospho-antibody ( 5 ) , western blotting ( 1 , 5 )
Relevant cell line - cell type - tissue:
liver ( 4 ) , macrophage-peritoneum ( 2 ) , MEF (fibroblast) ( 1 , 3 , 5 )

Upstream Regulation
Treatments:
acadesine ( 1 ) , ionizing_radiation ( 5 )

Downstream Regulation
Effects of modification on MDM4:
molecular association, regulation ( 1 , 3 )
Effects of modification on biological processes:
cell cycle regulation ( 1 ) , signaling pathway regulation ( 3 )
Induce interaction with:
14-3-3 gamma (human) ( 3 ) , 14-3-3 gamma (mouse) ( 1 )

References 

1

He G, et al. (2014) AMP-Activated Protein Kinase Induces p53 by Phosphorylating MDMX and Inhibiting Its Activity. Mol Cell Biol 34, 148-57
24190973   Curated Info

2

Wu X, et al. (2012) Investigation of receptor interacting protein (RIP3)-dependent protein phosphorylation by quantitative phosphoproteomics. Mol Cell Proteomics 11, 1640-51
22942356   Curated Info

3

Lee JH, et al. (2012) Hypoxia Activates Tumor Suppressor p53 by Inducing ATR-Chk1 Kinase Cascade-mediated Phosphorylation and Consequent 14-3-3γ Inactivation of MDMX Protein. J Biol Chem 287, 20898-903
22556425   Curated Info

4

Zhou J (2009) CST Curation Set: 7426; Year: 2009; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: HXXp[ST]
Curated Info

5

Wang YV, et al. (2009) Increased radioresistance and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-activated kinases. Cancer Cell 16, 33-43
19573810   Curated Info

6

Rikova K (2008) CST Curation Set: 4789; Year: 2008; Biosample/Treatment: cell line, Dana Farber-KTL(LN)-5/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info